Recruiting

Use of CGM in Kidney Transplant Recipients

The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.

ClinicalTrials.gov IDNCT04783441

PhaseNA

Enrollment80

SponsorUniversity of California, Davis

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes

About this study

Interventions

Device: Dexcom G6 — access to continuous glucose monitoring in the Dexcom G6 arm 24/7
Device: Dexcom G6 blinded sensor — retrospective access to continuous glucose profile after 10 days of wear

Primary outcomes

Time in Range (70-180 mg/dl) (70 days)

Eligibility information

Inclusion Criteria: 1. Age 18 or above 2. Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min 3. Person with Type 2 Diabetes and on insulin 4. Access to home wi-fi connection Exclusion Criteria: 1. Person with Type 1 Diabetes 2. Patients taking hydroxyurea 3. Patient unable to wear the Dexcom G6 device at all times for any reason 4. Must be able to test blood glucose with meter 4x a day when on blinded CGM. 5. Presence of clinically significant visual or cognitive impairment 6. Illiterate 7. Prisoners 8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding 9. Presence of clinically unstable cardiovascular disease 10. Active malignancy treatment

Study locations

UC Davis Health, Sacramento, California 95817 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.